Today, GE HealthCare (Nasdaq: GEHC) and DeepHealth, Inc., a global
leader in AI-powered health informatics and a wholly-owned
subsidiary of RadNet, Inc. (Nasdaq: RDNT), announced a strategic
collaboration to further the innovation, commercialization, and
adoption of AI in imaging. Together, the two companies aim to
develop SmartTechnology™ solutions that harness the transformative
power of AI to address key challenges across the imaging value
chain, including helping increase the efficiency of imaging
interpretation and reporting, enabling collaboration across care
teams, improving the clinical interpretation of images, and
enhancing operational efficiency and productivity. These new
SmartTechnology solutions will seek to combine GE HealthCare’s
imaging expertise and scale, RadNet’s deep experience in care
delivery, and DeepHealth’s AI-powered health informatics portfolio
to elevate patient care through improved end-to-end clinical and
operational workflows.
With the global cancer burden continuing to rise,2 health
systems face increasing challenges and seek solutions to enhance
early detection and diagnosis when treatment can be most effective.
To help address these challenges and demonstrate the promise of
this strategic relationship, the two companies will first work to
bring together DeepHealth’s AI-based
SmartMammo™ 1 workflow and clinical solution
and GE HealthCare’s patient-centric Senographe
Pristina™ mammography system to add AI-powered
clinical imaging support to breast cancer screening.
GE HealthCare’s Senographe Pristina mammography system was
designed to ease anxiety the moment the patient enters the exam
room. It features an inviting gantry with elegant lighting and
rounded shapes, as well as a soft-curved surface that welcomes
patients into a space of comfort and support – with 83% of patients
rating their experience with Senographe Pristina better and more
comfortable than previous exams.3
RadNet’s DeepHealth SmartMammo is an AI-powered SaaS solution
designed to seamlessly integrate into existing breast cancer
diagnostic workflows, enhancing diagnostic accuracy4 and workflow
efficiency. By embedding imaging informatics into advanced
mammography systems, the solution can support high-volume breast
cancer screening programs. The SmartMammo offering will work to
prioritize cases based on suspicion level and ensure seamless
integration and interoperability with existing healthcare IT
infrastructure.
SmartMammo includes: 1) a cloud-native smart enterprise image
viewer with PACS functionality that enables fast image loading and
real-time data rendering of multimodality images, accessible from
any workstation and location, 2) integration with radiologist
worklists and reporting tools to streamline the workflow, and 3) a
suite of clinical AI detection tools that offers automatic lesion
localization and degree of suspicion that are effective in diverse
populations and dense breast tissue. 1, 4 The cloud-native
architecture of the DeepHealth OS powering SmartMammo simplifies
support and maintenance while allowing for seamless feature updates
and functionality enhancements without any downtime.
Through this collaboration, the two companies also seek to
include Smart Alerts, a DeepHealth workflow solution to be
integrated with Senographe Pristina that will utilize rapid AI
processing with the goal of alerting imaging sites to cases with
potentially suspicious lesions in minutes. This kind of solution
aims to empower same-day diagnostic exams, follow-up compliance,
and reduced anxiety for women with potentially suspicious
findings.
"We are thrilled to collaborate with GE HealthCare to accelerate
the adoption of AI-powered technologies in radiology," said Kees
Wesdorp, President and CEO of RadNet’s Digital Health division. "By
combining our pioneering cloud-native operating system, DeepHealth
OS, and our AI-powered health informatics portfolio with GE
HealthCare’s cutting-edge imaging technology, we are poised to
revolutionize large-scale diagnostic and screening programs,
streamline radiology workflows, and improve patient outcomes. This
collaboration aims to empower healthcare providers with the tools
they need to deliver more effective and personalized care at
scale."
“GE HealthCare has a legacy of imaging and AI innovation and is
committed to our continued pursuit of new technologies that push
the boundaries of what is possible to enable precision care. This
new collaboration with DeepHealth harnesses our combined strengths
to address critical challenges in healthcare today,” explained
Roland Rott, President & Chief Executive Officer of Imaging for
GE HealthCare. “As we look to make more personalized,
patient-centered breast care a reality – AI continues to show great
promise in breast cancer screening from early detection and risk
prediction, to reduced callbacks and more efficient workflows for
breast imaging providers. We are excited to bring the power of
imaging and AI together to elevate personalized breast care for
those facing this difficult diagnosis.”
The two companies’ agreement will enable GE Healthcare to
distribute SmartMammo and other DeepHealth solutions to imaging
providers in the United States as part of GE HealthCare’s
comprehensive portfolio of imaging technologies.
In addition to collaborating on SmartMammo, GE HealthCare and
RadNet’s DeepHealth intend to explore areas of further
collaboration for SmartTechnology solutions in other modalities and
clinical domains, to expand the access to and impact of AI-based
workflows.
For more information, visit the GE HealthCare (#7330) and
DeepHealth (#1340) booths at the Radiological Society of North
America 2024 Annual Meeting.
About GE HealthCare Technologies Inc.GE
HealthCare is a leading global medical technology, pharmaceutical
diagnostics, and digital solutions innovator, dedicated to
providing integrated solutions, services, and data analytics to
make hospitals more efficient, clinicians more effective, therapies
more precise, and patients healthier and happier. Serving patients
and providers for more than 125 years, GE HealthCare is advancing
personalized, connected, and compassionate care, while simplifying
the patient’s journey across the care pathway. Together our
Imaging, Advanced Visualization Solutions, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from diagnosis, to therapy, to monitoring. We are a $19.6 billion
business with approximately 51,000 colleagues working to create a
world where healthcare has no limits. Follow us
on LinkedIn, X, Facebook, Instagram, and Insights for the latest
news, or visit our website https://www.gehealthcare.com for more
information.
About RadNet, Inc.RadNet, Inc. is the leading
national provider of freestanding, fixed-site diagnostic imaging
services in the United States based on the number of locations and
annual imaging revenue. RadNet has a network of 398 owned and/or
operated outpatient imaging centers. RadNet’s markets include
Arizona, California, Delaware, Florida, Maryland, New Jersey, New
York and Texas. In addition, RadNet provides radiology information
technology and artificial intelligence solutions marketed under the
DeepHealth brand, teleradiology professional services and other
related products and services to customers in the diagnostic
imaging industry. Together with affiliated radiologists, and
inclusive of full-time and per diem employees and technologists,
RadNet has a total of over 10,000 employees. For more information,
visit http://www.radnet.com.
About DeepHealthDeepHealth is a wholly-owned
subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the
umbrella brand for all companies within RadNet's Digital Health
segment. DeepHealth provides AI-powered health informatics with the
aim of empowering breakthroughs in care through imaging. Building
on the strengths of the companies it has integrated and is
rebranding (i.e., eRAD Radiology Information and Image
Management Systems and Picture Archiving and Communication System,
Aidence lung AI, DeepHealth and Kheiron breast AI and
Quantib prostate and brain AI), DeepHealth leverages advanced
AI for operational efficiency and improved clinical outcomes in
lung, breast, prostate, and brain health. At the heart of
DeepHealth’s portfolio is a cloud-native operating system -
DeepHealth OS - that unifies data across the clinical and
operational workflow and personalizes AI-powered workspaces for
everyone in the radiology continuum. Thousands of radiologists at
hundreds of imaging centers and radiology departments around the
world use DeepHealth solutions to enable earlier, more reliable,
and more efficient disease detection, including in large-scale
cancer screening programs. DeepHealth’s human-centered,
intuitive technology aims to push the boundaries of
what's possible in
healthcare. https://deephealth.com/
Forward Looking Statement This press release
contains “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Forward-looking statements, including
statements regarding the capabilities of RadNet, GE Healthcare and
DeepHealth’s informatics, hardware and software product portfolios
and the collaboration’s impact on radiology practices and
healthcare workflow, are expressions of our current beliefs,
expectations, and assumptions regarding the future of our business,
future plans and strategies, projections, and anticipated future
conditions, events and trends. Forward-looking statements can
generally be identified by words such as: “anticipate,” “intend,”
“plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,”
“strategy,” “future,” “likely,” “may,” “should,” “will” and similar
references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Because forward-looking
statements relate to the future, they are inherently subject to
uncertainties, risks and changes in circumstances that are
difficult to predict and many of which are outside of our control.
Our actual results and financial condition may differ materially
from those indicated in the forward-looking statements. Therefore,
you should not place undue reliance on any of these forward-looking
statements.
For media inquiries, reach out to:
GE HealthCareEmily NilesGlobal Communications
Leader for WHXREmail: emily.niles@gehealthcare.com
DeepHealthAndra AxenteCommunications
DirectorPhone: +31 614 440971Email: andra.axente@deephealth.com
RadNet, Inc.Mark StolperExecutive Vice
President and Chief Financial Officer310-445-2800
1 510(k) pending for use with GE HealthCare.2
https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services3
Data on file, GE Healthcare. 83% of patient assessed the exam as
more comfortable than previous. IPSOS Patient Satisfaction Study
sponsored by GE Healthcare, conducted with 315 patients across 2
sites in Europe.4 Kim et al. Impact of a Categorical AI System for
Digital Breast Tomosynthesis on Breast Cancer Interpretation by
Both General Radiologists and Breast Imaging Specialists. Radiol
Artif Intell. 2024. doi: 10.1148/ryai.230137.
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Oct 2024 to Nov 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Nov 2023 to Nov 2024